JPRN-UMIN000003043已完成未知
A multi-center, randomised study comparing thalidomide and bortezomib for multiple myeloma as maintenance therapy after autologous stem cell transplantation - A multi-center, randomised study comparing thalidomide and bortezomib for multiple myeloma as maintenance therapy after autologous stem cell transplantation
niversity of Tokyo Hospital, Department of Hematology and Oncology0 个研究点目标入组 200 人开始时间: 2010年1月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Allergy for thalidomide, Bortezomib, mannitol,and boron. 2. A woman during pregnancy or potential pregnancy 3. Patients unable to comply with safety management procedures of thalidomide. 4. Patients who cannot stop drugs or therapy restricted in this trial. 5. Patients who are recognized as inadaptable for this trial.
研究者
相似试验
进行中（未招募）
Unknown
Reducing chronic breathlessness in adults by following a self-guided, internet-based supportive interventioAdults living with chronic breathlessness due to malignant and non-malignant diseasesRespiratoryISRCTN13121835King's College Hospital NHS Foundation Trust246
进行中（未招募）
1 期
A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a plus placebo vs. pegylated interfeorn-alfa-2a plus tenofovir for the treatment of chronic delta hepatitis- The Hep-Net International Delta hepatits Interventional Trial II (HIDIT-II) - HIDIT-IITo compare the virological efficacy (HDV-RNA) and safety of 96 weeks of therapy with pegylated interferon-alfa-2a plus tenovofir to 96 weeks of therapy with pegylated interferon-alfa-2a plus placebo for the treatment with chronic delta hepatits virus.MedDRA version: 9.1Level: LLTClassification code 10047455Term: Viral hepatitis B without mention of hepatic coma, with hepatitis deltaEUCTR2008-005560-13-GRMedizinische Hochschule Hannover70
已完成
不适用
A multicenter randomised study comparing the efficacy of adefovir dipivoxil versus pegylated interferon alpha-2a plus placebo versus adefovir dipivoxil plus peglyated interferon alpha-2a for the treatment of chronic delta hepatitisAdults with chronic delta hepatitisInfections and InfestationsISRCTN83587695Hannover Medical School (MHH) (Germany)69
进行中（未招募）
1 期
Treatment of delta hepatitis with pegylated interferon-alfa-2a and tenofovir or placeboTo compare the virological efficacy (HDV-RNA) and safety of 96 weeks of therapy with pegylated interferon-alfa-2a plus tenovofir to 96 weeks of therapy with pegylated interferon-alfa-2a plus placebo for the treatment with chronic delta hepatits virus.MedDRA version: 15.1Level: LLTClassification code 10047455Term: Viral hepatitis B without mention of hepatic coma, with hepatitis deltaSystem Organ Class: 100000004862EUCTR2008-005560-13-DEMedizinische Hochschule Hannover70
进行中（未招募）
不适用
A multicenter, randomized, controlled study comparing the efficacy and safety of 48 weeks of 40kD branched pegylated interferon alfa-2a (PEGASYS, Ro 25-8310) versus 96 weeks of PEGASYS, alone or in combination with 100 mg lamivudine for 48 weeks in patients with HBeAg-negative chronic hepatitis B.Treatment of chronic hepatitis B, HBeAg-negativeMedDRA version: 14.1Level: PTClassification code 10019731Term: Hepatitis BSystem Organ Class: 10021881 - Infections and infestationsEUCTR2004-002985-39-ITROCHE